The concept of endometriosis and strategies for its treatment are reviewed. Treatment is mainly endocrine-based, using progestogens, danazol and luteinizing hormone-releasing hormone (LHRH) agonists. Such treatment is complex, and therapy strategies have to be tailored to the individual; the choice of treatment, therefore, depends on the metabolic and side-effects of each compound.
Introduction
The prevalence of endometriosis in the female population of reproductive age is estimated to be 6-44% (Vercellini and Crosignani, 1993) . However, our understanding of this phenomenon is changing because the histological definition of endometriosis as being endometrial glands and stroma outside the uterine cavity does not fulfil the criterion of a disease. Endometriosis as a disease is defined as 'the presence of ectopic endometrium, in association with evidence of cellular activity in the lesions and of progression, such as the formation of adhesions, or by its interference with normal physiological processes' (Audebert et al, 1992) . With respect to this definition, there is increasing evidence that subtle peritoneal lesions should no longer be considered as a disease which is present or not, but rather as an event occurring intermittently in most, if not all, women (Koninckx, 1994) . Therefore, modern research needs to concentrate on those factors which discriminate between endometriosis as a physiological process and endometriosis as a disease in order to define those patients who should be treated surgically and/or medically. As there are a lot of unanswered questions in this field of interest, today's therapeutic concepts are based solely on the macroscopic and, if possible, on the histological verification of endometriosis.
With regard to medical therapy, it seems to be likely that future endocrine strategies will vary depending on the aim of treatment, including elimination of endometriotic implants, relief of pain and induction of pregnancy. Recent studies are often heterogenous in the population treated and the length of medical treatment regimens. Recent investigations compare 3 months with 6 months of U.Cirkel endocrine therapy, but include patients in whom endometriosis was operatively confirmed within 24 months of admission into the study (Hornstein et al, 1995) . Until now, however, the operative procedure with histological verification of the disease is the gold standard. Even with modern ultrasonographic approaches, histological diagnosis of endometriosis in ovarian cysts is found only in about 78% of the adnexal masses that are suspicious in ultrasound examinations (Mais et al, 1993) . On the other hand, despite advances in imaging techniques, no correlation has been found between clinical symptomatology and the anatomical site of the disease (Fedele et al., 1990) , nor is there any correlation between subjective symptomatology and the stage of endometriosis as defined in the current revised American Fertility Society (rAFS) classification (Vercellini et al., 1996) . It is questionable whether symptomatology is a sufficient parameter in evaluating efficacy of any medical treatment, especially as it has been demonstrated that pain which had been assumed to be caused by endometriosis was influenced by each personality type (Gomibuchi et al, 1993) and that placebo therapy can influence painful menstruation in 41% of cases (Kauppila and Ronnberg, 1985) . With infertility, endometriosis becomes even more enigmatic. Until now, despite theoretical links, it has not been well established whether endometriosis causes infertility. Therefore, data in the current literature are controversial and sometimes misleading in understanding treatment necessity and modality.
Endometriosis symptomatology score
Although subjective, the cardinal symptoms reported by endometriosis patients include dysmenorrhoea, dyspareunia and pelvic discomfort/pain. Symptoms elicited upon gynaecological examination are pelvic tenderness and induration. In order to have a means of judging the therapeutic effectiveness and of comparing complaints, either during individual medical attendance or before and after any kind of medical treatment, a severity profile score of symptoms and findings has to be introduced. The scoring system established by Biberoglu and Behrman (1981) (Table I) is a subjective rating scale (+ = mild; ++ = moderate; + + + = severe) based on the patients' self-assessment of pain and the gynaecological palpation of the attending physician. Dysmenorrhoea comprises a minor loss of work efficiency (mild) and a complete incapacitation for 1 or more days (severe). Dyspareunia is defined as a limitation of sexual activity ranging from tolerated discomfort (mild) to sexual abstinence (severe). Nonmenstrual pelvic pain is defined as occasional discomfort (mild) and permanent use of analgesics (severe). A physical examination is comprehensive in pelvic tenderness which means an inability of pelvic palpation in severe cases and genital induration (severe forms with frozen uterus and nodular adnexa). Objective parameters in this scoring system are clearly missing. Physical examination can be aggravated by the patients' operative history (one or more laparotomies, e.g. for endometriosis) and abdominal muscular defence. Uterus freely mobile, induration in the cul-de-sac
•According to Biberoglu and Behrman, 1981. causes for endometriosis-associated pain are multiple, and contributing factors including sexual dysfunction and conflict, affective disorders, a history of sexual abuse and other detrimental development experiences make the disease even more complex (Rock, 1993) . Until now, more objective parameters have been missing, so the comparison of medical and/or surgical therapeutic attempts has to be based on the available scoring systems.
Endometriosis and infertility
In the general population, the monthly conception rate is ~20-30% when counting only live births. There is a great variability between couples and, even when the assumption is made that there are no totally sterile patients, 2-4% of these will remain without conception after 2 years (Querleu et al, 1993) . With regard to this background information, endometriosis-associated infertility remains one of the most difficult situations in reproductive medicine because the prevalence of endometriosis in the infertile population is estimated to be 20-40% (Mahmmod and Templeton, 1991) . There are various mechanisms which might explain how endometriosis lowers monthly fecundity rates (Table II) . The most probable reason for inhibiting conception is the anatomical damage of pelvic organs including tubo-ovarian adhesions and tubal distortions. When there are normal Fallopian tubes and ovaries without any adhesions, the exact mechanism by which endometriosis impairs fertility remains speculative. To date, ovarian deficiency, altered peritoneal environment as well as implantation failure and early abortions have been considered as interesting hypotheses. There is a lack of sufficient data to establish a highly significant correlation between these non-91 Korte (1970) Lembke (1986) Luciano (1988) Moghissi ( anatomical alterations and reproductive failure in humans with endometriosis. In the absence of objectively-confirmed mechanisms, endometriosis may simply be a co-factor of infertility. So far, many of the studies dealing with the subject are retrospective analyses of the data with a doubtful value. A clearly-defined control group is often missing and the results are seldom balanced with regard to the amount of time spent undergoing medical therapy during which conception was impossible. Therefore, pregnancy rates after a specific treatment for endometriosis, surgical and/or medical, should be evaluated critically.
Progestogens in endometriosis
Continuous application of progestogens will lead to a hypo-oestrogenic, hypergestagenic endocrine environment causing initial decidualization of endometrial tissue with eventual atrophy. Progestational agents are administered in a variety of protocols with different dosages and duration of therapy (Table HI) . The divergent results may be explained by the lack of an obligatory pretreatment, histological verification of the disease and the non-homogeneous treatment modalities. Donnez et al. (1990) investigated the effect of lynestrenol on ovarian endometriosis using a second-look microsurgical procedure by laparotomy. There were only minor changes in the objective AFS score which were comparable to those of another progestogenic compound used in the study (2.5 mg gestrinone, three times a week). The pregnancy rate of 52% was achieved after the microsurgical removal of residual implants, so that a direct effect of lynestrenol on the pregnancy rate in endometriosis patients cannot be stated. Moghissi and Boyce (1976) observed an excellent subjective improvement of symptoms (100%) after 30 mg of medroxyprogesterone acetate (MPA), but the pregnancy rate varied according to the male factor (fertile husbands: 90%, deficient male factor: 20%) and the anatomical situation of the genital organs (one pregnancy out of 26 women with severe endometriosis). Therefore, a sole effect of the progestogenic compound could not be proven. As a second-look operation was not obligatory in the same study, the effect on the objective improvement of endometriotic implants could not be reported. Different dosages of MPA (20 mg versus 250 mg) were investigated by Willemsen et al. (1985) . They found a higher cure rate with the higher dosage of MPA. On the other hand, higher dosages of MPA and derivatives of nortestosterone such as lynestrenol are known to be linked to metabolic side effects, e.g. on lipid metabolism. As well as an often observed poor cycle control with lower dosages of progestogens (breakthrough bleeding), it was shown that, after the end of endocrine treatment with the higher dosages of these compounds, cycle recovery is delayed with signs of amenorrhoea and anovulation. This is a major disadvantage, especially in women in whom the induction of pregnancy is the aim of the treatment. According to these observations, therapy with progestogens may be favoured in those patients in whom pain-relief is to be achieved. On the other hand, data so far available do not exclude any positive effects of progestogens on endometriotic implants themselves. Therefore, randomized placebo-controlled clinical trials are necessary in order to better evaluate the potential benefits of these compounds.
Luteinizing hormone-releasing hormone agonist and danazol in endometriosis
The ethisterone derivative danazol, which has been in general use for this common gynaecological disorder since 1973, is considered as the 'gold standard' of endometriosis therapy. The mode of action of danazol is complex and involves the inhibition of steroidogenesis (gonads, adrenal gland), the interaction with the androgen, progesterone, glucocorticoid receptor and the binding proteins sex hormone-binding globulin and corticosteroid-binding globulin (Barbieri, 1990) . These effects lead to a hypo-oestrogenic, hyperandrogenic environment which is unfavourable for the growth of endometriotic implants. Unfortunately, danazol therapy is accompanied by many general, metabolic, hypo-oestrogenic and hyperandrogenic side-effects. Therefore, the search for alternatives in the endocrine therapy of endometriosis was accelerated. In 1981, luteinizing hormonereleasing hormone (LHRH) analogues (agonists) were first used in clinical trials Claesson (1989) Dmowski (1989) Fedele (1989) Henzl (1988) Kennedy (1990) NEET (1992) Rolland (1990) Shaw (1992) Tummon (1989) Wheeler ( Naf. = nafarelin; Bus. = buserelin; Gos. = goserelin; Leupr. = Leuprorelin.
as a medical treatment for endometriosis. These substances have a significantly longer half-life than the natural decapeptide LHRH and show a high affinity for gonadotrophin-releasing hormone receptors. During treatment with these compounds, the initial phase of release of luteinizing hormone (LH) and follicle stimulating hormone (FSH) is followed by a decrease in gonadotrophin secretion. These pituitary side-effects lead to a hypogonadal state with a marked suppression of ovarian oestrogen and progesterone production (Barbieri, 1990) . In order to prove the efficacy of LHRH agonists in endometriosis therapy, they have to be compared with danazol in clinical trials. Today there are several studies available investigating the clinical results of danazol and LHRH analogues in comparative multicentre trials (Table IV) . A placebo arm in these studies is missing, but it is ethically questionable whether a stage III or IV disease, e.g. with an involvement of both ovaries, should be treated expectantly. On the other hand, in these comparative trials quite a high number of patients were included with stage I endometriosis (American Fertility Society, 1985) , which implies an overtreatment and a delay for women in whom pregnancy is the only aim of therapy. Interestingly, Henzl etal. (1988) as well as the Nafarelin European Endometriosis Trial Group (NEET, 1992) found a progression of endometriosis (5.6 and 8% respectively) despite treatment. However, as for the decrease in the adhesion score under endocrine therapy reported by the same study groups, it has to be questioned whether these findings are the result of an error inherent in the clinical scoring procedure induced by the number of participating study centres. So far, clinical results for LHRH agonists and danazol are comparable and with no significant differences between substances. Based on the operative findings from a second-look operation, the reduction in total rAFS score ranges from 20.8-82.2%. With the subjective complaints, treatment efficacy seems to be even more pronounced (maximally 100% amelioration of symptoms, Claesson and Bergquist, 1989) .
In order to find out whether methodological problems of multicentre trials, such as different investigators and laboratory evaluations, non-homogeneity of dosages and treatment periods, have any influence on the results of a comparative study between danazol and an LHRH analogue, 55 pre-menopausal women with histologically-proven endometriosis were treated at a single centre (Department of Obstetrics and Gynaecology, University of Muenster, Germany; Cirkel et al, 1995) . Stage I endometriosis (rAFS) was excluded from the protocol. During 24 weeks, 30 women were treated with the LHRH analogue depot triptorelin (Decapeptyl®; Ferring, Kiel, Germany; 3.75 mg every 4 weeks i.m.), and 25 patients were prescribed danazol (Winobanin®; Sanofi Winthrop, Munich, Germany; three times 200 mg orally).
Due to the pharmacological properties of both substances, there were distinct differences in their endocrine effects. With regard to the gonadotrophins LH and FSH, which were measured by commercially available radioimmunoassays, the LHRH analogue led to a significant decrease in both pituitary hormones compared with the steroid danazol (Figure 1) . A sharp decrease of FSH after 4 weeks of treatment with the analogue was remarkable; this was followed by a slight, but steady increase in this gonadotrophin throughout the remaining treatment period. In comparison, FSH remained elevated after an initial rise during treatment with danazol. The effects on gonadotrophins were accompanied by characteristic alterations in ovarian function. The LHRH analogue, triptorelin, led to a sharp fall in mean serum oestradiol concentrations to the post-menopausal range (<80 pmol/1), which was significantly lower than changes induced by danazol (Figure 2) . At the same time, progesterone concentrations were deeply suppressed, which is indicative of a lack of luteinization. As far as the suppression of oestradiol is concerned, it was suggested by Homstein et al. (1995) that patients with lower oestradiol values (<40 pg/ml) generally would have better symptom relief than less hypo-oestrogenic patients. This is in accordance with Barbieri (1992) pronounced hypo-oestrogenic side effects. Concerning the androgenic parameters, the influence of the LHRH analogue was negligible in comparison with danazol, where a marked hyperandrogenic environment could be confirmed. Although these differences in the endocrine effects of the LHRH analogue triptorelin and danazol could be shown, both drugs are equally effective in achieving symptomatic relief of endometriosis. Gynaecological complaints reported by all patients before endocrine therapy included dysmenorrhoea (triptorelin depot: 82.7%; danazol: 83.4%), pelvic pain (48.3 and 50% respectively) and dyspareunia (34.5 and 33.4% respectively). Symptoms elicited upon gynaecological examination were pelvic induration (51.7 and 70.8% respectively) and tenderness (13.8 and 8.3% respectively). After 24 weeks of treatment, the percentage of patients showing a reduction of symptoms with triptorelin depot was: dysmenorrhoea down 82.7%, pelvic pain down 24.2%, dyspareunia down 24.2%; compatible figures with danazol were: dysmenorrhoea down 83.4%, pelvic pain down 25%, dyspareunia down 33.4%, as well as of pelvic induration (down 6.9% and 14.3% respectively) and tenderness (down 13.8% and 8.3% respectively) could be ascertained for both substances. There were some changes, however, in the severity profile after 24 weeks of endocrine treatment for both danazol and triptorelin (Figure 3) .
Concerning symptomatic relief and a reduction of objective rAFS score, there were no significant differences between the steroid danazol and the LHRH analogue triptorelin (Cirkel et al, 1995) . This is in accordance with the other comparative trials (Table IV) , although multicentre studies have the disadvantage of multi-investigator heterogeneity and non-comparability of laboratory investigations. The choice of treatment for endometriosis patients is therefore dependent on the side effect profile and the metabolic alterations of danazol and the prescribed LHRH analogue.
As far as pregnancy rates after specific therapy are concerned, data are even more confusing. Results vary from 0% (Burrey et al, 1989) to 70% (Tummon et al, 1989) (Table IV) . This non-homogeneity is mainly due to the different AFS stages being treated (including stage I disease; is it really a disease?), a different observation period after the end of treatment and concomitant therapy of infertility factors other than endometriosis, if present.
On the other hand, prolonged LHRH analogue suppression of ovarian function before ovarian stimulation in endometriosis patients undergoing assisted reproduction techniques may overcome some causes of infertility in these women. Nakamura et al. (1992) reported a significant increase in the clinical pregnancy rate/transfer in patients after the ultralong compared with the long protocol (67 versus 27%, P <0.05). Similar results were found by Oehninger et al. (1989) . They reported a pregnancy rate of 41.6% after LHRH agonist pretreatment (control cycle without LHRH analogue: 16.6%). With respect to the stage of the disease, patients suffering from stage III or IV endometriosis had a more dramatic improvement with LHRH agonists than those with minimal or mild disease. In a retrospective study by Olivennes et al. (1995) , patients with endometriosis as the sole factor for infertility and in-vitro fertilization (IVF) treatment had a delivery rate of 38.9% per cycle (41.9% per retrieval, 43.2% per transfer). They suggested that pituitary suppression before gonadotrophin stimulation for IVF may be beneficial for all endometriosis patients.
Another problem which remained unsolved until now is the determination of the long-term recurrence rate of endometriosis after medical treatment. Available data refer mainly to the patients' subjective complaints (Table IV) . Fedele et al. (1989) found a discrepancy between these subjective results (recurrence rate 56.3-56.7%) and the histologically-proven relapse of the disease (13.3-15.6%). According to Waller and Shaw (1993) , particularly those patients with severe forms of endometriosis at the outset are more likely to suffer from a recurrence of the disease (overall recurrence rate: 43.8%). With these investigations in mind, it becomes even clearer that today's available medical therapy does not cure endometriosis. Appropriate means to detect and to prevent (postpone?) a relapse of the disease are thought to be necessary.
Conclusions and perspectives
Medical management of women with endometriosis is complex, and therapy strategies have to be individualized with respect to the patients' age and complaints. To date, medical therapy is mainly based upon endocrine treatment modalities including progestogens, danazol and LHRH agonists. These substances are obviously equally effective in terms of reduction in implant scores proven upon operation and relief of subjective symptoms. Therefore the choice of treatment should depend on the metabolic and general side-effects of each compound. On the other hand, the disease and its symptoms may recur following the different endocrine treatment modalities, indicating that available hormonal therapy strategies for endometriosis do not eradicate the disease. We have to reevaluate the conception of endometriosis as a microcosm of endometrial tissue. Only ~60% of endometriotic implants are in phase with the cyclicity of the uterine endometrium (Bergquist et al, 1984) . The so-called 'ectopic endometrial implant' often seems to be independent of those factors regulating the eutopic endometrium. Therefore efforts have to be strengthened to understand the local factors involved in the development and progression of the implants and to discriminate between those lesions representing a disease and physiological alterations. These mechanisms include local inflammatory reactions with altered immune response as well as auto-and paracrine regulatory principles of the endometriotic tissue. The possible role of immunomodulatory substances such as glucocorticoids (Simon et al, 1992) and pentoxifylline (Steinleitner et al, 1991) as well as direct inhibitory effects of danazol and LHRH agonists on the cell growth of endometriotic implants have to be elucidated in the future research and therapy of endometriosis.
